# Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

- Source: PR Newswire
- Published: 2026-10-25T01:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/zhejiang-wenda-pharma-announces-positive-results-from-phase-ii-trial-of-oral-bet-inhibitor-nhwd-870-hcl-at-the-2026-esmo-annual-meeting-302918672.html
- Canonical: https://groundlevelnews.com/story/zhejiang-wenda-pharma-announces-positive-results-from-phase-ii-trial-o-a6fa67/

SHAOXING, China, Oct. 25, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC)....

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._